Polynucleotides and exosomes for hair loss

Polynucleotides and exosomes are not interchangeable injectable categories. Polynucleotides are DNA-derived material; exosome products are presented as extracellular vesicle preparations. Neither category has settled, high-quality clinical evidence establishing reliable hair-density or shedding outcomes. A UK reader should examine product identity, evidence, consent, practitioner accountability and plans for complications before proceeding.

What this comparison can establish

Polynucleotide and exosome treatments are often discussed together in hair-loss marketing, but they describe different material categories and should not be treated as equivalents. Polynucleotides are preparations of nucleotide chains, commonly described in aesthetic practice as PN or, in some contexts, PDRN. Exosomes are extracellular vesicles. That distinction matters because a label such as “regenerative” does not identify the material, its concentration, its intended use or the evidence behind a proposed result. [Evidence status: definitional]

For a person noticing thinning or shedding, the central question is not which label sounds more advanced. It is whether there is published human evidence for the specific intervention, route, scalp condition and outcome being proposed. Hair density, hair-shaft diameter, photographic appearance and reported shedding are different outcomes. A change in one does not automatically establish a change in another. [Evidence status: outcome interpretation]

This page compares the categories at a level relevant to a UK reader considering injections. It does not provide a diagnosis, select an intervention, or advise whether treatment is suitable for an individual. It also does not examine exosome manufacture or sourcing. The exosome patient decision is covered separately by Exosomes Therapy. [Scope]

Contents

• What each injectable category is
• What evidence can and cannot show about density and shedding
• How a proposed course should be described
• Recovery, aftercare and adverse-event planning
• UK questions on accountability and records

Readers seeking background on the polynucleotide substance, claimed mechanism, treatment areas, safety and consultation should use this title’s sections on what polynucleotides are, the claimed mechanism, what a course involves, side effects and complications, and questions to ask. [Editorial route]

What polynucleotide and exosome injectables actually are

A polynucleotide is a chain of nucleotides, the molecular units associated with DNA and RNA. In aesthetic injectable discussions, PN and PDRN may be used as related but not necessarily identical labels. A reader should not assume that a broad category name establishes that two preparations have the same composition, route of administration, dose, quality controls or intended purpose. The product name and documentation are needed to establish what is actually being proposed. [Evidence status: definitional]

An exosome is a type of extracellular vesicle released by cells. Saying that a preparation is “exosome-based” does not, by itself, establish its contents, purity, activity, route or clinical effect. Those manufacturing and characterisation questions are outside this title’s remit. They should not be replaced by general statements about cell communication. [Scope]

The comparison should therefore begin with documents and outcomes, not a claim that one category is inherently stronger, safer or more natural. [Evidence status: decision rule]

What published evidence supports for density and shedding

Hair-loss research has a basic interpretive problem: hair cycles change over time, and visible appearance can be affected by hair length, styling, lighting, baseline severity and concurrent treatment. A before-and-after photograph is not a reliable measure of density unless the method, timing and comparison conditions are described. Self-reported shedding can be meaningful to the person experiencing it, but it is not interchangeable with a counted hair-density endpoint. [Evidence status: methodology]

For both polynucleotide and exosome injectables, a cautious reader should distinguish biological plausibility from demonstrated clinical benefit. Laboratory findings, animal work and mechanistic discussion may generate a hypothesis. They do not establish that an injection produces durable, patient-relevant improvement in human scalp hair. Small uncontrolled studies can also be difficult to interpret because they cannot reliably separate an intervention from natural fluctuation, other treatments or expectation effects. [Evidence status: evidence hierarchy]

Neither category should be described as proven to restore hair density or stop shedding solely on the basis of category-level claims. A defensible claim would need to identify the preparation, participants, comparator where present, assessment method, follow-up period and adverse events. It would also need to make clear whether the outcome was measured density, a clinical assessment, photography, participant report or something else. [Evidence status: claim standard]

Ask whether a cited paper is about the actual material and scalp route proposed, rather than a related molecule, a topical product, a different procedure or a laboratory model. If that connection cannot be made, the evidence is indirect. [Evidence status: applicability]

How a course should be structured and spaced

There is no category-wide course schedule that can be inferred safely for either polynucleotide or exosome injections in hair loss. A proposed series may vary in number of visits, injection technique, interval, total treatment period and any review point. Variation is not evidence of individualisation by itself. The relevant question is whether the schedule follows a stated protocol and whether that protocol is supported by evidence relevant to the product and purpose. [Evidence status: treatment planning]

Before a first appointment, a provider should be able to explain what happens at each visit: the area to be treated, the intended route, who performs the injection, what is recorded, what outcome will be reviewed and what would lead to stopping rather than continuing. A plan that treats repeated attendance as inevitable without defining a review criterion leaves the reader unable to judge whether there is benefit, no change or deterioration. [Evidence status: consent process]

A sensible record can include baseline scalp photographs taken under comparable conditions, the date, the reported pattern of shedding, concurrent hair or scalp treatments, and any adverse effects after each session. Records do not prove efficacy, but they are more useful than relying on memory or promotional imagery. They can also matter if a reaction develops or a different clinician later needs to understand what was done. [Evidence status: documentation]

Decision rule: do not begin a course until the proposed product, injector, route, review point, stopping rule and adverse-event contact route have been provided in writing.

Cost can be affected by the product, number of appointments, practitioner time, setting and follow-up arrangements. This page gives no price comparison because a meaningful, dated and like-for-like verified dataset is not available here. [Scope]

Recovery and aftercare: what should be planned

Any scalp injection can cause temporary local effects such as discomfort, tenderness, swelling, redness, bruising or small marks at injection sites. The likelihood and duration depend on factors including the procedure, area, technique and individual response. A person should not be promised a uniform recovery period for a category of injectable. [Evidence status: injection risk]

Aftercare instructions should be specific to the procedure actually performed. They should explain ordinary expected local effects, what activities or products the provider advises avoiding for a stated period, when the person may wash or handle the scalp, and how to obtain help outside routine opening hours. Vague instructions to “take it easy” do not tell a person how to identify a problem or whom to contact. [Evidence status: aftercare standard]

Urgent assessment may be needed where symptoms are severe, rapidly worsening or unusual, including escalating pain, spreading redness, marked swelling, discharge, fever or feeling unwell. A person with signs suggesting a severe allergic reaction should seek emergency help. These examples are not a diagnostic list, and a provider should not imply that remote reassurance can replace clinical assessment where concerning symptoms are present. [Evidence status: escalation]

For any suspected adverse reaction, retain the product details, batch information if available, treatment date, photographs and a contemporaneous account of symptoms. The UK Yellow Card scheme allows suspected side effects to be reported to the Medicines and Healthcare products Regulatory Agency. The title’s “Recording a reaction” and “What to do if something goes wrong” sections explain the value of a clear record. [Evidence status: reporting route]

Questions a UK reader should ask before either treatment

Ask questions before a booking becomes a commitment. The first group concerns identity: what exactly is the product, what is its intended use, what route will be used and why is that route proposed for this scalp concern? A category term is not a sufficient answer. Ask for the name of the person who will inject, their professional registration where applicable, relevant training, insurance arrangements and how accountability works if that person is unavailable. [Evidence status: accountability]

The next group concerns evidence. Ask for the published human evidence that is being relied on, the study type, the date, the outcome measured and whether it concerns the same product and route. Ask whether hair density and shedding are being discussed separately. A practitioner should be able to describe uncertainty without converting a preliminary finding into a promise. [Evidence status: evidence communication]

Ask about assessment and consent: what alternative explanations for hair change have been considered, what medical history matters, whether current medication or scalp disease could alter risk, and how the plan accounts for concurrent treatments. A treatment consultation is not a substitute for diagnosis of a new, sudden, patchy, inflammatory or otherwise concerning hair change. [Evidence status: limits]

• What written information will I receive before treatment?
• What outcome will be assessed, and at what review date?
• What are the known and unknown risks for this route?
• Who handles a complication, and how can I reach them?
• What product and batch details will be recorded in my notes?
• What would make you advise against proceeding or stopping the course?

UK regulation and professional duties can change and may differ according to setting, profession and nation. The title’s “UK position on who may inject”, “Prescribing and remote prescribing” and “Premises, insurance and redress” sections provide the regulatory context without treating a cosmetic procedure as risk-free. [Evidence status: regulatory context]

Limits of this comparison

This is a category comparison for adults considering a proposed UK hair-loss injection. It is not medical advice, a diagnosis, a product recommendation, a ranking, or a substitute for an examination by an appropriately qualified clinician. It does not establish that either category is effective for any particular type or cause of hair loss. It does not cover exosome manufacture, sourcing or laboratory characterisation, which fall outside this title’s defined subject. [Scope]

It also does not apply as a protocol for self-injection, home treatment, treatment of children, pregnancy or breastfeeding decisions, or management of an acute reaction. Those situations require individual clinical and, where relevant, urgent assessment. A person should disclose allergies, relevant medical conditions, medicines, previous reactions and current scalp treatments to the clinician responsible for the consultation. [Evidence status: safety boundary]

Evidence changes only when new, relevant research is published and can be assessed in context. A new paper does not automatically resolve uncertainty, particularly if it is small, uncontrolled, short in follow-up or uses an outcome that does not answer the claim being made. The evidence register and open-questions sections of this title set out how claims are separated from unanswered questions. [Editorial method]